Efficacy and safety of CD19 CAR T-cell therapy in relapsed/refractory follicular lymphoma: A systematic review and meta-analysis
CAR T-cell therapy produces strong responses in hard-to-treat lymphoma patients, though manageable side effects require careful medical oversight during treatment.
A PROSPERO-registered systematic review of 6 studies found CD19 CAR T-cell therapy achieved 93.5% overall response rate and 84.5% complete response rate in R/R follicular lymphoma, supporting its use in patients with limited treatment options. Cytokine release syndrome occurred in 61.4% and neurological events in 33.6%, highlighting manageable but significant toxicity requiring close monitoring.
What the study was
- Study design
- Systematic review and meta-analysis (6 studies; PROSPERO CRD420251133655)
- Population
- R/R follicular lymphoma patients treated with CD19 CAR T-cell therapy
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Curr Res Transl Med
Why it surfaced
PROSPERO-registered meta-analysis of CD19 CAR-T in R/R FL showing exceptional ORR 93.5%/CRR 84.5%; high-quality evidence synthesis directly relevant to hematologic malignancy and CAR-T watchlists.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.